BioMarin Takes One Step Closer To Profitability With Positive GALNS Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The orphan drug company reported positive Phase III data on its candidate for patients with the rare disease MPS IV and expects to file GALNS for FDA approval in the first quarter.
You may also be interested in...
BioMarin: A Rare Disease Specialist With An Eye On The Long-Term
BioMarin is in the midst of a pivotal year, with several near-term data catalysts, the most important of which will be Phase III data on GALNS for the rare disease MPS IV.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.